Trial Profile
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of an Intramuscular Formulation of Depot Olanzapine (Pamoate Salt) in Stable Schizophrenic Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Apr 2015
Price :
$35
*
At a glance
- Drugs Olanzapine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 16 Apr 2015 New trial record